Currently, the interest of researchers is predominantly focused on the use of PDE inhibitors specifically degrading both cAMP and cGMP or only cAMP, which, in the experimental models of PD, were administered alone or in combination with L-DOPA [11,13,35,36,37]. This evidence concerns the gene ALDH7A1 and Parkinson disease.